SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Susan L. Samson, Shereen Ezzat, AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease, Endocrine Practice, 2014, 20, 6, 608

    CrossRef

  2. 2
    Michele A Faulkner, Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease, Expert Opinion on Drug Safety, 2014, 13, 8, 1055

    CrossRef

  3. 3
    Manuela Jörg, Lauren T. May, Frankie S. Mak, Kiew Ching K. Lee, Neil D. Miller, Peter J. Scammells, Ben Capuano, Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2Aand Dopamine D2Receptors for the Potential Treatment of Parkinson’s Disease, Journal of Medicinal Chemistry, 2014, 141224135534003

    CrossRef

  4. 4
    Dorothy M Gujral, Sanjeev Bhattacharyya, Cardiac manifestations of gastrointestinal carcinoid tumor, Future Cardiology, 2013, 9, 4, 479

    CrossRef

  5. 5
    Luigi Michele Pavone, Russell A. Norris, Distinct Signaling Pathways Activated by “Extracellular” and “Intracellular” Serotonin in Heart Valve Development and Disease, Cell Biochemistry and Biophysics, 2013, 67, 3, 819

    CrossRef

  6. 6
    Fernando L. Vale, Armen R. Deukmedjian, Shan Hann, Vitra Shah, Anthony D. Morrison, Medically treated prolactin-secreting pituitary adenomas: when should we operate?, British Journal of Neurosurgery, 2013, 27, 1, 56

    CrossRef

  7. 7
    Imju Jeong, Bok Hee Choi, Sang June Hahn, Pergolide block of the cloned Kv1.5 potassium channels, Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 2, 125

    CrossRef

  8. 8
    Irina I. Koleva, Teris A. van Beek, Ans E. M. F. Soffers, Birgit Dusemund, Ivonne M. C. M. Rietjens, Alkaloids in the human food chain – Natural occurrence and possible adverse effects, Molecular Nutrition & Food Research, 2012, 56, 1
  9. 9
    Chandrasekar Palaniswamy, William H. Frishman, Wilbert S. Aronow, Carcinoid Heart Disease, Cardiology in Review, 2012, 20, 4, 167

    CrossRef

  10. 10
    Nermien A. Ibrahim, Rania A. Zidan, Rehab A. Karam, Does green tea have an ameliorative effect against cabergoline-induced cardiotoxicity in adult male albino rats? A histological and biochemical study, The Egyptian Journal of Histology, 2012, 35, 1, 13

    CrossRef

  11. 11
    A. Elenkova, R. Shabani, K. Kalinov, S. Zacharieva, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment, European Journal of Endocrinology, 2012, 167, 1, 17

    CrossRef

  12. 12
    Gianluca Trifirò, M. Mostafa Mokhles, Jeanne P. Dieleman, Eva M. van Soest, Katia Verhamme, Giampiero Mazzaglia, Ron Herings, Cynthia de Luise, Douglas Ross, Guy Brusselle, Annamaria Colao, Wilhelm Haverkamp, Rene Schade, Guy van Camp, Renzo Zanettini, Miriam C. Sturkenboom, Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinsonʼs Disease and Hyperprolactinaemia, Drug Safety, 2012, 35, 2, 159

    CrossRef

  13. 13
    M. Mostafa Mokhles, Gianluca Trifirò, Jeanne P. Dieleman, Mendel D. Haag, Eva M. van Soest, Katia M.C. Verhamme, Giampiero Mazzaglia, Ron Herings, Cynthia de Luise, Douglas Ross, Guy Brusselle, Annamaria Colao, Willem Haverkamp, Rene Schade, Guy van Camp, Renzo Zanettini, Miriam C.J.M. Sturkenboom, The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease, Pharmacological Research, 2012, 65, 3, 358

    CrossRef

  14. 14
    Arimantas Tamasauskas, Kestutis Sinkunas, Adomas Bunevicius, Andrius Radziunas, Daina Skiriute, Vytenis P. Deltuva, Transsphenoidal surgery for microprolactinomas in women: results and prognosis, Acta Neurochirurgica, 2012, 154, 10, 1889

    CrossRef

  15. 15
    Camelia-Maria Monoranu, Stefan Kircher, Angelika Schmitt, Peter Riederer, Manfred Gerlach, Uniform pattern of immunohistochemical localization of serotonin 5-HT2 receptors in human aortic, mitral, pulmonary and tricuspid heart valves: Implication for the pathomechanism of valvular heart disease following treatment with dopamine agonists, Basal Ganglia, 2012, 2, 2, 87

    CrossRef

  16. 16
    Ashok Krishnaswami, Kathleen B. Albers, Robin D. Fross, James J. Jang, Sarah B. Berkheimer, Valerie C. Kwai Ben, Stephen K. VanDenEeden, Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation, Pharmacoepidemiology and Drug Safety, 2012, 21, 3
  17. 17
    Carrie R. Muh, Nelson M. Oyesiku, Principles of Neurological Surgery, 2012,

    CrossRef

  18. 18
    Hiroshi Katsuki, Shotaro Michinaga, Sleep Hormones, 2012,

    CrossRef

  19. 19
    Edward R. Laws, John A. Jane, Kamal Thapar, Brain Tumors, 2012,

    CrossRef

  20. 20
    Shin Hisahara, Shun Shimohama, Dopamine Receptors and Parkinson's Disease, International Journal of Medicinal Chemistry, 2011, 2011, 1

    CrossRef

  21. 21
    Olivier Rascol, Andres Lozano, Matthew Stern, Werner Poewe, Milestones in Parkinson's disease therapeutics, Movement Disorders, 2011, 26, 6
  22. 22
    Vibeke Guldbrand Rasmussen, Karen Østergaard, Erik Dupont, Steen Hvitfeldt Poulsen, The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists, Movement Disorders, 2011, 26, 5
  23. 23
    Christopher J. Earley, Richard P. Allen, Wayne Hening, Sleep Disorders, 2011,

    CrossRef

  24. 24
    Mary P. Gillam, Mark E. Molitch, The Pituitary, 2011,

    CrossRef

  25. 25
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  26. 26
    Shotaro Michinaga, Akinori Hisatsune, Yoichiro Isohama, Hiroshi Katsuki, An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture, Neuroscience Research, 2010, 68, 4, 315

    CrossRef

  27. 27
    Santiago Perez-Lloret, Olivier Rascol, Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease, CNS Drugs, 2010, 24, 11, 941

    CrossRef

  28. 28
    Mark J. Millan, From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease, Pharmacology & Therapeutics, 2010, 128, 2, 229

    CrossRef

  29. 29
    Yuichi Inoue, Kenji Kuroda, Koichi Hirata, Naohisa Uchimura, Tatsuo Kagimura, Tetsuo Shimizu, Long-term open-label study of pramipexole in patients with primary restless legs syndrome, Journal of the Neurological Sciences, 2010, 294, 1-2, 62

    CrossRef

  30. 30
    Angelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, Mitsutoshi Yamamoto, Werner H Poewe, A reassessment of risks and benefits of dopamine agonists in Parkinson's disease, The Lancet Neurology, 2009, 8, 10, 929

    CrossRef

  31. 31
    Marcos Lahera Vargas, Carlos Escobar Cervantes, Carmen Alameda Hernando, César Varela Da Costa, Cabergolina en la hiperprolactinemia y enfermedad valvular cardíaca, Endocrinología y Nutrición, 2009, 56, 8, 412

    CrossRef

  32. 32
    William L. Baker, Dee Silver, C. Michael White, Jeffrey Kluger, Jeffrey Aberle, Aarti A. Patel, Craig I. Coleman, Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis, Parkinsonism & Related Disorders, 2009, 15, 4, 287

    CrossRef

  33. 33
    Sanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis, Joseph Davar, Drug-induced fibrotic valvular heart disease, The Lancet, 2009, 374, 9689, 577

    CrossRef

  34. 34
    Jacques Hamon, Steven Whitebread, Valerie Techer-Etienne, Helene Le Coq, Kamal Azzaoui, Laszlo Urban, In vitrosafety pharmacology profiling: what else beyond hERG?, Future Medicinal Chemistry, 2009, 1, 4, 645

    CrossRef

  35. 35
    Malcolm Steiger, W. Jost, F. Grandas, G. Van Camp, Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review, Journal of Neural Transmission, 2009, 116, 2, 179

    CrossRef

  36. 36
    S. Droogmans, D. Kerkhove, B. Cosyns, G. Van Camp, Role of echocardiography in toxic heart valvulopathy, European Journal of Echocardiography, 2009, 10, 4, 467

    CrossRef

  37. 37
    Sakima A. Smith, Alan D. Waggoner, Lisa de las Fuentes, Victor G. Davila-Roman, Role of Serotoninergic Pathways in Drug-Induced Valvular Heart Disease and Diagnostic Features by Echocardiography, Journal of the American Society of Echocardiography, 2009, 22, 8, 883

    CrossRef

  38. 38
    Luigi Michele Pavone, Anna Spina, Silviana Rea, Dionea Santoro, Vincenzo Mastellone, Pietro Lombardi, Luigi Avallone, Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-β1 signalling, Journal of Molecular and Cellular Cardiology, 2009, 47, 5, 691

    CrossRef

  39. 39
    Neil Herring, Cezary Szmigielski, Harald Becher, Niki Karavitaki, John A. H. Wass, Valvular heart disease and the use of cabergoline for the treatment of prolactinoma, Clinical Endocrinology, 2009, 70, 1
  40. 40
    Feriha Ozer, Raziye Tiras, Sibel Cetin, Oya Ozturk, Tuba Aydemir, Serkan Ozben, Hasan Meral, Sibel Kizkin, Halit Bader, Beste Ozben, Valvular heart disease in patients with Parkinson’s disease treated with pergolide, levodopa or both, Journal of Clinical Neuroscience, 2009, 16, 1, 83

    CrossRef

  41. 41
    George A. Mensah, Valvular Heart Disease: A Companion to Braunwald's Heart Disease, 2009,

    CrossRef

  42. 42
    Nicholas A. DeMartinis, Jayesh Kamath, Andrew Winokur, Contemporary Aspects of Biomedical Research - Drug Discovery, 2009,

    CrossRef

  43. 43
    Chandikumar S. Elangbam, Lauren E. Job, Leah M. Zadrozny, Joanna C. Barton, Lawrence W. Yoon, Lisa D. Gates, Nikki Slocum, 5-Hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats, Experimental and Toxicologic Pathology, 2008, 60, 4-5, 253

    CrossRef

  44. 44
    Gurutz Linazasoro, Conversion From Dopamine Agonists to Cabergoline, Clinical Neuropharmacology, 2008, 31, 1, 19

    CrossRef

  45. 45
    Stewart A. Factor, Current status of symptomatic medical therapy in Parkinson’s disease, Neurotherapeutics, 2008, 5, 2, 164

    CrossRef

  46. 46
    M.D. Cheitlin, Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation, Yearbook of Cardiology, 2008, 2008, 428

    CrossRef

  47. 47
    Qanta A. Ahmed, Effects of Common Medications Used for Sleep Disorders, Critical Care Clinics, 2008, 24, 3, 493

    CrossRef

  48. 48
    Luigi Michele Pavone, Anna Spina, Roberta Lo Muto, Dionea Santoro, Vincenzo Mastellone, Luigi Avallone, Heart valve cardiomyocytes of mouse embryos express the serotonin transporter SERT, Biochemical and Biophysical Research Communications, 2008, 377, 2, 419

    CrossRef

  49. 49
    Tatiana Mancini, Felipe F. Casanueva, Andrea Giustina, Hyperprolactinemia and Prolactinomas, Endocrinology and Metabolism Clinics of North America, 2008, 37, 1, 67

    CrossRef

  50. 50
    Jessica K. Devin, Vipul T. Lakhani, Benjamin F. Byrd, Lewis S. Blevins, Prevalence of Valvular Heart Disease in a Cohort of Patients Taking Cabergoline for Management of Hyperprolactinemia, Endocrine Practice, 2008, 14, 6, 672

    CrossRef

  51. 51
    Jennifer E. Smith, Jerry M. Tolson, Recognition, diagnosis, and treatment of restless legs syndrome, Journal of the American Academy of Nurse Practitioners, 2008, 20, 8
  52. 52
    Pankaj Satija, William G Ondo, Restless Legs Syndrome, CNS Drugs, 2008, 22, 6, 497

    CrossRef

  53. 53
    Kazuo Yamashiro, Miki Komine-Kobayashi, Taku Hatano, Takao Urabe, Hideki Mochizuki, Nobutaka Hattori, Yoshitaka Iwama, Hiroyuki Daida, Michi Sakai, Takeo Nakayama, Yoshikuni Mizuno, The frequency of cardiac valvular regurgitation in Parkinson's disease, Movement Disorders, 2008, 23, 7
  54. 54
    Ubaldo Bonuccelli, Roberto Ceravolo, The safety of dopamine agonists in the treatment of Parkinson's disease, Expert Opinion on Drug Safety, 2008, 7, 2, 111

    CrossRef

  55. 55
    F. Bogazzi, S. Buralli, L. Manetti, V. Raffaelli, T. Cigni, M. Lombardi, F. Boresi, S. Taddei, A. Salvetti, E. Martino, Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia, International Journal of Clinical Practice, 2008, 62, 12
  56. 56
    Takashi Sato, Akio Kikuchi, Noriko Onoue, Tetuya Hiramoto, Mikio Oumi, Junichi Onodera, Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergolive, Rinsho Shinkeigaku, 2008, 48, 7, 486

    CrossRef

  57. 57
    D. Dupuy, J. P. Lesbre, P. Gérard, M. Andrejak, O. Godefroy, Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Course following treatment modifications, Journal of Neurology, 2008, 255, 7, 1045

    CrossRef

  58. 58
    Birgit Högl, Handbook of Sleep Disorders, Second Edition, 2008,

    CrossRef

  59. 59
    Pasquale Montagna, Wayne Hening, Handbook of Sleep Disorders, Second Edition, 2008,

    CrossRef

  60. 60
    Gülay Kenangil, Sibel Özekmekçi, Lale Koldas, Taylan Sahin, Ethem Erginöz, Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline, Clinical Neurology and Neurosurgery, 2007, 109, 4, 350

    CrossRef

  61. 61
    Markku Partinen, Challenging issues: Sleep–wake, augmentation and quality of life, Sleep Medicine, 2007, 8, S19

    CrossRef

  62. 62
    Wayne A. Hening, Current Guidelines and Standards of Practice for Restless Legs Syndrome, The American Journal of Medicine, 2007, 120, 1, S22

    CrossRef

  63. 63
    René Schade, Frank Andersohn, Samy Suissa, Wilhelm Haverkamp, Edeltraut Garbe, Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation, New England Journal of Medicine, 2007, 356, 1, 29

    CrossRef

  64. 64
    Masahiro Nagai, Noriko Nishikawa, Hayato Yabe, Hiroyoko Moritoyo, Takashi Moritoyo, Yuji Shigematsu, Masahiro Nomoto, Dopamine agonists and valvular heart disease in Japanese patients with Parkinson's disease, Journal of Neurology, 2007, 254, S4, IV54

    CrossRef

  65. 65
    Mitsutoshi Yamamoto, Tadahisa Uesugi, Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery, Journal of Neurology, 2007, 254, S5, 74

    CrossRef

  66. 66
    Øyvind Hauso, Björn I. Gustafsson, Jan P. Loennechen, Astrid K. Stunes, Ivar Nordrum, Helge L. Waldum, Long-term serotonin effects in the rat are prevented by terguride, Regulatory Peptides, 2007, 143, 1-3, 39

    CrossRef

  67. 67
    E. Růžička, H. Línková, M. Pěnička, O. Ulmanová, L. Nováková, J. Roth, Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide, Journal of Neurology, 2007, 254, 11, 1575

    CrossRef

  68. 68
    Gregor Simonis, Joerg T. Fuhrmann, Ruth H. Strasser, Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists, Movement Disorders, 2007, 22, 13
  69. 69
    Wolfgang H. Oertel, Claudia Trenkwalder, Marco Zucconi, Heike Benes, Diego Garcia Borreguero, Claudio Bassetti, Markku Partinen, Luigi Ferini-Strambi, Karin Stiasny-Kolster, State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome, Movement Disorders, 2007, 22, S18
  70. 70
    Y Naidu, K Ray Chaudhuri, Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson’s disease, Expert Opinion on Drug Delivery, 2007, 4, 2, 111

    CrossRef

  71. 71
    Renzo Zanettini, Angelo Antonini, Gemma Gatto, Rosa Gentile, Silvana Tesei, Gianni Pezzoli, Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease, New England Journal of Medicine, 2007, 356, 1, 39

    CrossRef

  72. 72
    Susann Junghanns, Joerg T. Fuhrmann, Gregor Simonis, Christian Oelwein, Rainer Koch, Ruth H. Strasser, Heinz Reichmann, Alexander Storch, Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study, Movement Disorders, 2007, 22, 2
  73. 73
    Neurology Board Review, 2007,

    CrossRef

  74. 74
    Trond Kvernmo, Sebastian Härtter, Erich Burger, A review of the receptor-binding and pharmacokinetic properties of dopamine agonists, Clinical Therapeutics, 2006, 28, 8, 1065

    CrossRef

  75. 75
    Cabergoline and Mitral Regurgitation, New England Journal of Medicine, 2006, 354, 4, 420

    CrossRef

  76. 76
    Cindy Zadikoff, Paula Rochon, Anthony Lang, Cardiac Valvulopathy Associated with Pergolide Use, The Canadian Journal of Neurological Sciences, 2006, 33, 01, 27

    CrossRef

  77. 77
    Heinz Reichmann, Anja Bilsing, Reinhard Ehret, Wolfgang Greulich, Jörg B. Schulz, Andreas Schwartz, Olivier Rascol, Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease, Journal of Neurology, 2006, 253, S4, iv36

    CrossRef

  78. 78
    Chandikumar S. Elangbam, John G. Wehe, Joanna C. Barton, David L. Krull, Abraham Nyska, Torrie Crabbs, Grace E. Kissling, Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy – A possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats?, Experimental and Toxicologic Pathology, 2006, 58, 2-3, 89

    CrossRef

  79. 79
    Lars Sl??rdal, Olav Spigset, Heart Failure Induced by Non-Cardiac Drugs, Drug Safety, 2006, 29, 7, 567

    CrossRef

  80. 80
    C. Hofmann, U. Penner, R. Dorow, H. H. Pertz, S. J??hnichen, R. Horowski, K. P. Latt??, D. Palla, B. Schurad, Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties, Clinical Neuropharmacology, 2006, 29, 2, 80

    CrossRef

  81. 81
    J. Montplaisir, M. L. Fantini, A. Desautels, M. Michaud, D. Petit, D. Filipini, Long-term treatment with pramipexole in restless legs syndrome, European Journal of Neurology, 2006, 13, 12
  82. 82
    Miklos Z Molnar, Marta Novak, Istvan Mucsi, Management of Restless Legs Syndrome in Patients on Dialysis, Drugs, 2006, 66, 5, 607

    CrossRef

  83. 83
    Mark E Molitch, Prolactin-secreting tumors: what’s new?, Expert Review of Anticancer Therapy, 2006, 6, 9s, S29

    CrossRef

  84. 84
    B. Schurad, R. Horowski, S. Jähnichen, T. Görnemann, J. Tack, H.H. Pertz, Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: Interactions with α1-, 5-HT2- and H1-receptors, Life Sciences, 2006, 78, 20, 2358

    CrossRef

  85. 85
    Luigi Ferini-Strambi, Ropinirole: use in restless legs syndrome, Future Neurology, 2006, 1, 3, 269

    CrossRef

  86. 86
    Lisa L Ioannides-Demos, Joseph Proietto, Andrew M Tonkin, John J McNeil, Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity, Drug Safety, 2006, 29, 4, 277

    CrossRef

  87. 87
    M.E. Molitch, Severe Multivalvular Heart Disease: A New Complication of the Ergot Derivative Dopamine Agonists, Yearbook of Endocrinology, 2006, 2006, 427

    CrossRef

  88. 88
    Alan Diamond, Joseph Jankovic, Treatment of advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 8, 1181

    CrossRef

  89. 89
    Eun Joo Chung, Won Tae Yoon, Ji-Youn Kim, Won Yong Lee, Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide, Movement Disorders, 2006, 21, 4
  90. 90
    Ji-Youn Kim, Eun Joo Chung, Seung Woo Park, Won Yong Lee, Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists, Movement Disorders, 2006, 21, 8
  91. 91
    Cecilia Peralta, Elisabeth Wolf, Hannes Alber, Klaus Seppi, Silvana Müller, Sylvia Bösch, Gregor K. Wenning, Otmar Pachinger, Werner Poewe, Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study, Movement Disorders, 2006, 21, 8
  92. 92
    jean-marie launay, Odile Kellermann, Luc Maroteaux, 5-Hydroxytryptamine receptor 2B, AfCS-Nature Molecule Pages, 2005,

    CrossRef

  93. 93
    Tom H Johnston, Susan H Fox, Jonathan M Brotchie, Advances in the delivery of treatments for Parkinson’s disease, Expert Opinion on Drug Delivery, 2005, 2, 6, 1059

    CrossRef

  94. 94
    Sven Jähnichen, Reinhard Horowski, Heinz H. Pertz, Agonism at 5-HT2B receptors is not a class effect of the ergolines, European Journal of Pharmacology, 2005, 513, 3, 225

    CrossRef

  95. 95
    Alan S Pearlman, Carcinoid Heart Disease: Echocardiographic Recognition and Differential Diagnosis, American Heart Hospital Journal, 2005, 3, 2
  96. 96
    Kerry A. O'Connor, Bryan L. Roth, Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery, Nature Reviews Drug Discovery, 2005, 4, 12, 1005

    CrossRef

  97. 97
    Anthony E. Lang, Janis Miyasaki, C. Warren Olanow, A. Jon Stoessl, Oksana Suchowersky, Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease, The Canadian Journal of Neurological Sciences, 2005, 32, 03, 277

    CrossRef

  98. 98
    Bryan L. Roth, Receptor systems: Will mining the receptorome yield novel targets for pharmacotherapy?, Pharmacology & Therapeutics, 2005, 108, 1, 59

    CrossRef

  99. 99
    Ilia Itin, Cynthia L. Comella, Restless Legs Syndrome, Primary Care: Clinics in Office Practice, 2005, 32, 2, 435

    CrossRef

  100. 100
    Katherine L. Widnell, Cynthia Comella, Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations, Movement Disorders, 2005, 20, S11
  101. 101
    Wolfgang H. Jost, Dieter Angersbach, Ropinirole, a Non-Ergoline Dopamine Agonist, CNS Drug Reviews, 2005, 11, 3
  102. 102
    Vincent Setola, Bryan L Roth, Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen–phen’, Expert Opinion on Drug Metabolism & Toxicology, 2005, 1, 3, 377

    CrossRef

  103. 103
    J.-C. Corvol, M. Schüpbach, A.-M. Bonnet, Valvulopathies sous pergolide : revue critique de la littérature et conduite à tenir en pratique, Revue Neurologique, 2005, 161, 6-7, 637

    CrossRef

  104. 104
    Pinky Agarwal, Stanley Fahn, Steven J. Frucht, Diagnosis and management of pergolide-induced fibrosis, Movement Disorders, 2004, 19, 6
  105. 105
    Olivier Rascol, Atul Pathak, Haleh Bagheri, Jean-Louis Montastruc, Dopaminagonists and fibrotic valvular heart disease: Further considerations, Movement Disorders, 2004, 19, 12
  106. 106
    Reinhard Horowski, Sven Jähnichen, Heinz H. Pertz, Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role, Movement Disorders, 2004, 19, 12
  107. 107
    Olivier Rascol, Atul Pathak, Haleh Bagheri, Jean-Louis Montastruc, New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance, Movement Disorders, 2004, 19, 6
  108. You have free access to this content108
    Raymond G. Booth, John L. Neumeyer, Ross J. Baldessarini, Therapeutic and Diagnostic Agents for Parkinson's Disease, Burger's Medicinal Chemistry and Drug Discovery,